# US Vascular Stents Market > US Vascular Stents Market Research Report By Type (Drug-Eluting Stents, Bare-Metal Stents, Biodegradable Stents), By Application (Coronary Artery Disease, Peripheral Vascular Disease, Carotid Artery Disease), By Material (Metal Stents, Polymer Stents, Composite Stents) and By End Use (Hospitals, Cardiac Catheterization Labs, Ambulatory Surgical Centers) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 3.61% - **2024:** $ 1,695.67 Million - **2025:** $ 1,756.88 Million - **2035:** $ 2,504.63 Million - **Key Players:** Medtronic (US), Boston Scientific (US), Abbott Laboratories (US), B. Braun Melsungen AG (DE), Terumo Corporation (JP), Cordis Corporation (US), Cook Medical (US), Johnson & Johnson (US), Stryker Corporation (US) **Report ID:** MRFR/MED/18536-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-vascular-stents-market-20083 --- ## Market Summary ## **US Vascular Stents Market Overview** As per MRFR analysis, the US Vascular Stents Market Size was estimated at 1.64 USD Billion in 2023. The US Vascular Stents Market Industry is expected to grow from 1.7 USD Billion in 2024 to 2.5 USD Billion by 2035. The US Vascular Stents Market CAGR growth rate is expected to be around 3.568% during the forecast period from 2025 to 2035. ## **Key US Vascular Stents Market Trends Highlighted** The US Vascular Stents Market is witnessing significant growth driven by several key market drivers, including the rising prevalence of cardiovascular diseases and an aging population. The American Heart Association estimates that cardiovascular diseases remain a leading cause of death in the United States, creating a pressing demand for effective treatment options such as vascular stents. Furthermore, advancements in stent technology, including the development of drug-eluting stents, are enhancing the safety and efficacy of these devices, which boosts adoption rates in clinical settings. Opportunities in this market are emerging as a result of increased awareness regarding preventive healthcare. More patients are seeking consultations for early diagnosis and treatment, sparking demand for innovative stenting solutions. The shift toward minimally invasive procedures also aligns well with patient preferences, as these options typically offer quicker recovery times and less postoperative discomfort. This trend is fostering further research and development efforts by manufacturers looking to enhance product offerings. Recent trends in the US Vascular Stents Market emphasize patient-centric care and personalized medicine, as healthcare providers are increasingly focusing on tailoring treatments to individual patient needs. This shift in approach is driving collaborations between [medical device companies](../../../reports/africa-medical-devices-market/companies) and healthcare institutions to develop customized stent solutions. Additionally, the integration of digital health technologies is influencing the market, with advancements in monitoring and diagnostics allowing for better patient management and outcomes. As these trends evolve, they are likely to shape the future landscape of the vascular stent market in the United States. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Vascular Stents Market Drivers** ### **Increasing Prevalence of Cardiovascular Diseases** The US Vascular Stents Market Industry is significantly driven by the rising prevalence of cardiovascular diseases (CVDs) across the nation. According to the Centers for Disease Control and Prevention (CDC), approximately 697,000 Americans die from heart disease each year, which accounts for about 1 in every 5 deaths. As the population ages and risk factors such as obesity and diabetes become more prevalent, the demand for vascular stents is set to rise sharply. The American Heart Association also notes that nearly half of adults in the US have some form of cardiovascular disease, highlighting the pressing need for effective treatment options including vascular stents. This growing patient base seeking interventions reinforces the demand for vascular stents, paving the way for substantial market growth in the coming years. ### **Technological Advancements in Stent Design** Innovation in stent technology is another key driver propelling the US Vascular Stents Market Industry. Recent advancements such as drug-eluting stents that release medication to prevent artery re-narrowing, and bioresorbable stents that dissolve over time, are transforming treatment approaches. The Food and Drug Administration (FDA) has approved multiple new stent technologies in recent years, with some studies indicating a significant improvement in patient outcomes associated with these advanced stents. For example, data from a major clinical trial showed that drug-eluting stents can reduce the likelihood of restenosis by over 25% compared to bare-metal stents. Thus, continued Research and Development efforts in stent technology are crucial for growth in the market. ### **Government Initiatives and Funding** Government policies and funding initiatives for cardiovascular health are playing a vital role in the expansion of the US Vascular Stents Market Industry. The US Department of Health and Human Services has outlined health improvement strategies that prioritize reducing cardiovascular disease through preventative measures, research initiatives, and improved access to care. For instance, the federal government allocates substantial funds each year to healthcare programs that include treatment options like vascular stents. Programs such as the National Institutes of Health (NIH) support Research and Development in innovative cardiovascular treatment options, which indirectly promotes a favorable environment for the vascular stent market. These initiatives lead to better healthcare infrastructure and increase awareness about vascular treatment options among healthcare providers and patients alike. ## **US Vascular Stents Market Segment Insights** ### **Vascular Stents Market Type Insights** The US Vascular Stents Market is classified into multiple types, each playing a unique role in the treatment of cardiovascular diseases. Among the different types, Drug-Eluting Stents are significant as they are designed to release medication over time to prevent the growth of scar tissue in the artery lining, which can help reduce the risk of restenosis. This technology represents an important advancement in vascular interventions, enhancing patient outcomes and improving the quality of life for individuals with coronary artery disease. In contrast, Bare-Metal Stents are the traditional solution and remain a commonly used option due to their straightforward design and ease of use. While they lack drug-eluting capabilities, they serve as a viable alternative for certain patients, particularly those who may face complications with drug-eluting variations or who have specific medical conditions that necessitate simpler implant procedures. The choice between these two types often depends on a patient's specific condition and response to prior treatments. Another evolving area is Biodegradable Stents, which represent a cutting-edge option in the vascular stents market. As their materials are designed to dissolve over time, they offer the potential for less long-term complications and better integration with the natural structure of the artery. Their presence in the market reflects a growing trend towards more patient-friendly and less invasive choices. Overall, the segmentation of the US Vascular Stents Market into these distinct types is driven by the increasing need for effective treatment of cardiovascular diseases, varying patient profiles, and the integration of technological advancements. Trends such as hospital investments in advanced medical technologies and the growing prevalence of coronary artery diseases position these types as critical components of the market landscape. Each type demonstrates its significance through advancements in design and materials that address specific patient needs, indicating a trend towards more personalized medical solutions within the US healthcare system. The US Vascular Stents Market data supports the idea that the ongoing developments in vascular interventions are pivotal in continuing to improve treatment outcomes and patient satisfaction. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Vascular Stents Market Application Insights** The US Vascular Stents Market, specifically within the Application segment, encompasses various critical areas such as Coronary Artery Disease, Peripheral Vascular Disease, and Carotid Artery Disease, which are significant causes of morbidity and mortality in the population. Coronary Artery Disease remains a major health concern in the US, driving the need for effective stenting solutions to improve patient outcomes. Meanwhile, Peripheral Vascular Disease is particularly relevant due to its increasing prevalence associated with lifestyle factors like obesity and diabetes, which are notably affecting the US populace. Carotid Artery Disease also plays a crucial role, as it can lead to strokes, prompting advancements in stenting technologies to enhance the safety and efficacy of procedures. This segmentation reflects the urgent need for innovative treatments, while the growing geriatric population in the US presents both challenges and opportunities in the Vascular Stents Market. Overall, the focus on these applications highlights the importance of ongoing Research and Development initiatives aimed at improving the effectiveness of vascular interventions and ultimately improving patient quality of life. With the continuous advances in material sciences and minimally invasive techniques, the market dynamics remain conducive to growth and innovation in stent applications. ### **Vascular Stents Market Material Insights** The US Vascular Stents Market is significantly influenced by the Material segment, which comprises various types of stents including Metal Stents, Polymer Stents, and Composite Stents. Metal Stents have historically dominated due to their strength and durability, which are vital for vascular applications. The introduction of advanced alloys has improved their performance, catering to a broad range of patients. Meanwhile, Polymer Stents are gaining traction for their biocompatibility and flexibility, allowing for a less invasive approach and enhanced patient comfort. These stents are particularly appealing in cases where reduced risk of restenosis is a priority. Composite Stents, combining the benefits of both metal and polymer materials, are emerging as a viable option, potentially revolutionizing vascular interventions with their tailored properties. The growth drivers for the Material segment are fueled by technological advancements, increasing prevalence of cardiovascular diseases, and a growing aging population in the US. However, challenges such as regulatory hurdles and the high cost of innovative materials impact the market dynamics. Opportunities lie in expanding research and development efforts aimed at improving stent designs and materials, addressing both procedural efficiency and patient outcomes, ultimately enhancing the overall landscape of the US Vascular Stents Market. ### **Vascular Stents Market End Use Insights** The US Vascular Stents Market showcases a diverse End Use segment comprising Hospitals, Cardiac Catheterization Labs, and Ambulatory Surgical Centers, each playing a vital role in healthcare delivery. Hospitals dominate this segment, as they provide comprehensive diagnostic and treatment services for cardiovascular diseases, equipped with advanced technologies and skilled personnel. Cardiac Catheterization Labs are increasingly relevant due to the rise in minimally invasive procedures, enabling timely interventions. Ambulatory Surgical Centers have gained prominence with the growing preference for outpatient surgeries, leading to cost efficiency and improved recovery times for patients. With the increasing incidence of cardiovascular diseases in the US, the demand for vascular stents continues to grow, highlighting the necessity for these facilities. Each of these End Use categories significantly contributes to the overall dynamics of the US Vascular Stents Market, driven by evolving patient care standards and technological advancements in medical devices. The interplay of these segments underlines the importance of tailored approaches to meet the diverse needs of patients and healthcare providers alike. ## **US Vascular Stents Market Key Players and Competitive Insights** The US Vascular Stents Market is characterized by a highly competitive landscape where numerous companies vie for market share by offering innovative products and advanced technologies. This market has experienced significant growth due to the increasing prevalence of cardiovascular diseases, rising healthcare expenditures, and a growing aging population that necessitates interventional procedures. Companies in this space are focused on product differentiation, developing innovative designs and materials to enhance stent performance, reduce complications, and improve patient outcomes. Furthermore, regulatory approvals and the adoption of less invasive surgical techniques play a crucial role in shaping the competitive dynamics. As a result, key players continuously strive to expand their market presence through strategic partnerships, mergers and acquisitions, and by investing heavily in research and development. Bard Medical has established a solid foothold in the US Vascular Stents Market through its focus on high-quality products and customer-centric solutions. The company has a strong reputation for its commitment to innovation, ensuring that it remains relevant in a rapidly evolving industry. Bard Medical prides itself on robust manufacturing capabilities and a wide array of vascular access products, particularly in the design and delivery systems used in stenting procedures. A significant strength of Bard Medical lies in its strong distribution network, which allows for effective penetration into the market and maintaining strong relationships with healthcare providers. This network is complemented by the company's emphasis on rigorous clinical studies demonstrating the effectiveness of its products, which bolsters customer trust and confidence. Medtronic stands out in the US Vascular Stents Market with its extensive portfolio and a focus on advancing the treatment of vascular diseases. The company offers several key products that include drug-eluting stents and specialty stents designed for specific clinical applications. Medtronic's strengths lie not only in its innovative technology but also in its strategic approach to mergers and acquisitions that have bolstered its capabilities and market presence. The company has consistently invested in research and development, leading to the introduction of cutting-edge technologies that address unmet clinical needs. Medtronic's strong presence in the US is further enhanced by its collaborations with healthcare providers and institutions, facilitating improved patient outcomes through multidisciplinary approaches. Such collaborations, combined with a focus on education and training for healthcare professionals, solidify Medtronic's position as a leader in the vascular stent market, enabling it to maintain a competitive edge in an evolving healthcare landscape. ### **Key Companies in the US Vascular Stents Market Include** - Bard Medical - [**Medtronic**](https://www.medtronic.com/en-us/healthcare-professionals/products/cardiovascular/peripheral-biliary-stents.html#aq=%40pagetype%3D%22product-model%22&cq=%40products_group%3D%22Peripheral%20and%20biliary%20stents%22%20OR%20%40ontology_isa%3D%22Peripheral%20and%20biliary%20stents%22) - Abbott Laboratories - Boston Scientific - ASAHI INTECC - Conformis - Stryker - Volcano Corporation - Terumo - Cordis - Cook Medical - AngioDynamics - Philips - Johnson and Johnson - Biotronik ### **US Vascular Stents Market Industry Developments** The US Vascular Stents Market has seen significant developments recently, particularly with technological advancements and regulatory approvals. Medtronic received FDA clearance for its new drug-eluting stent, showcasing ongoing innovation in the field. Abbott Laboratories also reported growth due to the successful launch of its latest vascular devices, catering to an increasing patient population with cardiovascular conditions. In terms of Mergers and Acquisitions, Bard Medical acquired a smaller device manufacturer in June 2023, enhancing its product portfolio in the vascular stent category, while Cook Medical announced a partnership with AngioDynamics in August 2023 to bolster market presence. The market's valuation has been positively impacted by a growing aging population and rising incidences of coronary artery diseases, further stimulated by advancements in minimally invasive surgical techniques. Over the past two to three years, notable events such as Boston Scientific's introduction of new platforms in May 2022 and Stryker’s acquisition of a vascular technology firm in October 2021 have also shaped market dynamics. Overall, the US Vascular Stents Market continues to evolve with increased investment in Research and Development and strategic collaborations among key players. ## **US Vascular Stents Market Segmentation Insights** ### **Vascular Stents Market Type Outlook** - Drug-Eluting Stents - Bare-Metal Stents - Biodegradable Stents ### **Vascular Stents Market Application Outlook** - Coronary Artery Disease - Peripheral Vascular Disease - Carotid Artery Disease ### **Vascular Stents Market Material Outlook** - Metal Stents - Polymer Stents - Composite Stents ### **Vascular Stents Market End Use Outlook** - Hospitals - Cardiac Catheterization Labs - Ambulatory Surgical Centers ## Market Drivers ### Innovations in Stent Design and Materials Innovations in stent design and materials are significantly influencing the vascular stents market. The introduction of drug-eluting stents and bioresorbable stents has revolutionized treatment options, offering improved patient outcomes and reduced complications. The vascular stents market is witnessing a shift towards advanced materials that enhance biocompatibility and reduce restenosis rates. For instance, the use of polymer-based coatings and novel metallic alloys is becoming more prevalent. These advancements not only improve the efficacy of stenting procedures but also attract investment from medical device manufacturers, further propelling market growth. As research continues to yield new technologies, the vascular stents market is likely to expand. ### Rising Prevalence of Cardiovascular Diseases The increasing incidence of cardiovascular diseases in the US is a primary driver for the vascular stents market. According to the American Heart Association, cardiovascular diseases account for approximately 697,000 deaths annually, representing about 1 in every 5 deaths. This alarming statistic underscores the urgent need for effective treatment options, including vascular stents. As healthcare providers seek to address this growing health crisis, the demand for vascular stents is expected to rise. The vascular stents market is likely to experience significant growth as more patients require interventions such as angioplasty and stenting to manage their conditions. Furthermore, advancements in stent technology may enhance patient outcomes, further driving market expansion. ### Aging Population and Increased Healthcare Expenditure The aging population in the US is contributing to the growth of the vascular stents market. As individuals age, the risk of developing cardiovascular diseases increases, leading to a higher demand for vascular interventions. The US Census Bureau projects that by 2030, approximately 20% of the population will be 65 years or older. This demographic shift is accompanied by increased healthcare expenditure, with the Centers for Medicare & Medicaid Services estimating that national health spending will reach $6.2 trillion by 2028. Consequently, the vascular stents market is poised for growth as healthcare systems adapt to meet the needs of an older population requiring stenting procedures. ### Growing Awareness and Education on Cardiovascular Health Growing awareness and education regarding cardiovascular health are driving the vascular stents market. Public health campaigns and initiatives by organizations such as the American Heart Association are increasing knowledge about the risks associated with cardiovascular diseases. This heightened awareness encourages individuals to seek medical attention sooner, leading to earlier interventions and a greater need for vascular stents. The vascular stents market benefits from this trend as more patients are diagnosed and treated for conditions requiring stenting. Additionally, healthcare providers are increasingly emphasizing preventive measures, which may lead to a more proactive approach to cardiovascular health, further stimulating market demand. ### Expansion of Healthcare Infrastructure and Access to Care The expansion of healthcare infrastructure and improved access to care are pivotal drivers for the vascular stents market. The US government and private sector investments in healthcare facilities are enhancing the availability of advanced medical technologies, including vascular stents. As more hospitals and clinics adopt state-of-the-art equipment, the vascular stents market is likely to see increased utilization of stenting procedures. Furthermore, initiatives aimed at reducing healthcare disparities are improving access to cardiovascular care for underserved populations. This trend is expected to result in a broader patient base seeking vascular interventions, thereby driving growth in the vascular stents market. ## Future Outlook The [Vascular Stents Market](https://www.marketresearchfuture.com/reports/vascular-stents-market-1408) is projected to grow at a 3.61% CAGR from 2025 to 2035, driven by technological advancements, increasing cardiovascular diseases, and rising healthcare expenditures. **New opportunities:** - Development of bioresorbable stents for enhanced patient outcomes. Expansion into telehealth services for remote patient monitoring. Partnerships with healthcare providers for bundled payment models. By 2035, the vascular stents market is expected to achieve substantial growth, reflecting evolving healthcare needs. ## Segment Insights ### By Type: Drug-Eluting Stents (Largest) vs. Biodegradable Stents (Fastest-Growing) In the US vascular stents market, Drug-Eluting Stents dominate the market, accounting for a substantial share due to their advanced capabilities in reducing restenosis rates. Bare-Metal Stents hold a steady position, but their market share is gradually declining as healthcare providers increasingly favor the enhanced performance of Drug-Eluting Stents and the innovation of Biodegradable Stents. The growth trends indicate a strong shift towards Biodegradable Stents, which are considered the fastest-growing segment due to their biocompatibility and lower long-term complications. The increasing awareness of cardiovascular diseases and advances in technology are driving this growth. Continual innovation and positive patient outcomes further support the demand for Drug-Eluting Stents, ensuring their sustained dominance in the market. Drug-Eluting Stents (Dominant) vs. Biodegradable Stents (Emerging) Drug-Eluting Stents are recognized for their effectiveness in preventing restenosis, making them the dominant choice among healthcare professionals in the US vascular stents market. Their ability to release medication gradually allows for improved patient outcomes. In contrast, Biodegradable Stents present an emerging option that is gaining traction due to their substantial benefits, including reduced long-term complications and improved biocompatibility. As healthcare systems focus on sustainable solutions, Biodegradable Stents are projected to capture an increasing share of the market, appealing to both clinicians and patients who prioritize advancements in vascular health. Together, these segments are shaping the future of vascular intervention. ### By Application: Coronary Artery Disease (Largest) vs. Peripheral Vascular Disease (Fastest-Growing) In the US vascular stents market, the application segment is primarily dominated by Coronary Artery Disease (CAD), which significantly contributes to the overall market share. CAD treatment through vascular stents has become the standard, reflecting its substantial acceptance within the healthcare system. Peripheral Vascular Disease, while smaller in market share compared to CAD, is currently showing robust growth due to increasing prevalence, raising awareness, and advancements in stent technologies. The growth trends in the application segment are favorably driven by the aging population, which is prone to cardiovascular conditions, and improved diagnostic techniques that allow for earlier intervention. Additionally, with healthcare providers focusing on minimally invasive techniques, the demand for vascular stents for both CAD and Peripheral Vascular Disease is expected to rise. Innovations in stent designs, such as drug-eluting stents, further enhance their appeal and market adoption, positioning the market for continued expansion. Coronary Artery Disease (Dominant) vs. Carotid Artery Disease (Emerging) Coronary Artery Disease remains the dominant application in the US vascular stents market, characterized by its widespread incidence and the established protocols for stenting procedures. Patients suffering from CAD often require timely interventions, which drives the demand for these devices. In contrast, Carotid Artery Disease, while an emerging focus, is witnessing increasing recognition due to the rising number of cases and advancements in treatment options. As healthcare providers and patients become more informed about the importance of treating carotid artery blockages, the market for vascular stents designed for this application is poised for growth, conditional on strategic investments and continued clinical validations. ### By Material: Metal Stents (Largest) vs. Polymer Stents (Fastest-Growing) In the US vascular stents market, Metal Stents hold the largest market share due to their long-standing presence and proven performance. These stents are widely accepted in clinical practices for their strength and durability, contributing to their dominance. On the other hand, Polymer Stents, although currently a smaller segment, are rapidly gaining traction thanks to advancements in material technology and design innovations. Their enhanced flexibility and biocompatibility make them an attractive option for many healthcare providers. Growth trends indicate that Polymer Stents are emerging as the fastest-growing segment due to increasing demand for minimally invasive procedures and patient-specific solutions. Factors driving this growth include technological innovations, increased awareness about stent-associated complications, and a shift towards personalized medicine. As healthcare systems focus on delivering better outcomes with less invasive interventions, the demand for advanced stent technologies such as Polymer Stents will likely continue to rise, challenging the current dominance of Metal Stents. Metal Stents (Dominant) vs. Composite Stents (Emerging) Metal Stents are considered the dominant segment in the US vascular stents market, renowned for their robust mechanical properties and ability to support vessel integrity over time. Their established use in various procedures has led to a strong clinical trust among practitioners. Meanwhile, Composite Stents represent an emerging category that combines materials to leverage the benefits of both metal and polymer, allowing for improved flexibility and reduced clotting risks. These stents are designed to cater to specific patient needs, making them increasingly favored in complex vascular cases where traditional options may fall short. As the medical community becomes more focused on tailored treatment solutions, the market for Composite Stents is anticipated to grow rapidly. ### By End Use: Hospitals (Largest) vs. Cardiac Catheterization Labs (Fastest-Growing) In the US vascular stents market, hospitals hold the largest share, serving as the primary setting for vascular procedures due to their advanced facilities and a wide range of specialties. Cardiac catheterization labs are gaining prominence as they offer specialized services for cardiac procedures. The growth is influenced by the increasing prevalence of cardiovascular diseases, leading more patients to seek treatment in these facilities. The growth trends in the US vascular stents market are driven by advancements in stent technology and increasing patient awareness. Cardiac catheterization labs are experiencing rapid growth as they adopt innovative techniques and improve patient outcomes. In contrast, hospitals continue to invest in state-of-the-art equipment and facilities, ensuring they remain a key player in this sector. The combination of innovation and an expanding patient base presents a dynamic environment for both segments. Hospitals: Dominant vs. Cardiac Catheterization Labs: Emerging Hospitals are the dominant segment in the US vascular stents market, equipped with comprehensive resources, specialized staff, and advanced technologies that cater to a high volume of vascular procedures. They maintain a robust infrastructure to handle complex cases and provide postoperative care. On the other hand, cardiac catheterization labs are emerging as a vital component of the healthcare landscape, focusing on minimally invasive procedures that reduce recovery times and complications. These labs are increasingly favored for elective and urgent cardiac interventions, presenting opportunities for growth as they integrate modern techniques and enhance patient care options. This evolution reflects a shift towards more specialized settings that complement the established hospital framework. ## Competitive Benchmarking The vascular stents market is characterized by a dynamic competitive landscape, driven by technological advancements, increasing prevalence of cardiovascular diseases, and a growing aging population. Major players such as Medtronic (US), Boston Scientific (US), and Abbott Laboratories (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Medtronic (US) focuses on innovation through the development of next-generation stent technologies, while Boston Scientific (US) emphasizes strategic partnerships to expand its product portfolio. Abbott Laboratories (US) is leveraging its strong research capabilities to introduce cutting-edge solutions, thereby shaping a competitive environment that prioritizes technological superiority and patient outcomes.Key business tactics within this market include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The competitive structure appears moderately fragmented, with several players vying for market share. However, the collective influence of key players like Medtronic (US) and Boston Scientific (US) suggests a trend towards consolidation, as these companies seek to leverage their strengths to capture a larger share of the market. In October Medtronic (US) announced the launch of its latest drug-eluting stent, which incorporates advanced polymer technology aimed at improving patient outcomes. This strategic move is significant as it not only reinforces Medtronic's commitment to innovation but also positions the company to better compete against rivals by offering enhanced efficacy and safety profiles. Such advancements are likely to attract healthcare providers seeking the best treatment options for patients. In September Boston Scientific (US) entered into a partnership with a leading digital health company to integrate AI-driven analytics into its stent monitoring systems. This collaboration is pivotal, as it reflects a growing trend towards digitalization in healthcare, enabling real-time patient monitoring and personalized treatment plans. By embracing technology, Boston Scientific (US) is not only enhancing its product offerings but also improving patient engagement and outcomes. In August Abbott Laboratories (US) expanded its manufacturing capabilities in the US to meet the rising demand for its vascular stents. This expansion is crucial, as it allows Abbott to streamline its supply chain and respond more effectively to market needs. The investment in local manufacturing underscores Abbott's strategy to enhance operational efficiency while ensuring product availability, which is increasingly important in a competitive landscape. As of November current trends in the vascular stents market include a pronounced shift towards digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and improving patient care. Looking ahead, competitive differentiation is likely to evolve, with a greater emphasis on technological advancements and supply chain reliability rather than solely on price. This shift indicates a maturation of the market, where innovation and quality will play pivotal roles in determining success. ## Recent News & Developments The US Vascular Stents Market has seen significant developments recently, particularly with technological advancements and regulatory approvals. Medtronic received FDA clearance for its new drug-eluting stent, showcasing ongoing innovation in the field. Abbott Laboratories also reported growth due to the successful launch of its latest vascular devices, catering to an increasing patient population with cardiovascular conditions. In terms of Mergers and Acquisitions, Bard Medical acquired a smaller device manufacturer in June 2023, enhancing its product portfolio in the vascular stent category, while Cook Medical announced a partnership with AngioDynamics in August 2023 to bolster market presence. The market's valuation has been positively impacted by a growing aging population and rising incidences of coronary artery diseases, further stimulated by advancements in minimally invasive surgical techniques. Over the past two to three years, notable events such as Boston Scientific's introduction of new platforms in May 2022 and Stryker’s acquisition of a vascular technology firm in October 2021 have also shaped market dynamics. Overall, the US Vascular Stents Market continues to evolve with increased investment in Research and Development and strategic collaborations among key players. ## Report Scope | MARKET SIZE 2024 | 1695.67(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1756.88(USD Million) | | MARKET SIZE 2035 | 2504.63(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.61% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Medtronic (US), Boston Scientific (US), Abbott Laboratories (US), B. Braun Melsungen AG (DE), Terumo Corporation (JP), Cordis Corporation (US), Cook Medical (US), Johnson & Johnson (US), Stryker Corporation (US) | | Segments Covered | Type, Application, Material, End Use | | Key Market Opportunities | Advancements in biodegradable stents present new avenues for innovation in the vascular stents market. | | Key Market Dynamics | Technological advancements drive innovation in vascular stents, enhancing patient outcomes and reshaping competitive dynamics. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall market valuation of the US vascular stents market in 2024?** A: The overall market valuation was $1695.67 Million in 2024. **Q: What is the projected market valuation for the US vascular stents market by 2035?** A: The projected valuation for 2035 is $2504.63 Million. **Q: What is the expected CAGR for the US vascular stents market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during the forecast period 2025 - 2035 is 3.61%. **Q: Which companies are considered key players in the US vascular stents market?** A: Key players include Medtronic, Boston Scientific, Abbott Laboratories, and others. **Q: What are the main types of vascular stents available in the market?** A: The main types include Drug-Eluting Stents, Bare-Metal Stents, and Biodegradable Stents. **Q: What was the market valuation for Drug-Eluting Stents in 2024?** A: The market valuation for Drug-Eluting Stents ranged from $600.0 Million to $900.0 Million in 2024. **Q: How does the market for Bare-Metal Stents compare to Biodegradable Stents?** A: Bare-Metal Stents had a valuation between $700.0 Million and $900.0 Million, while Biodegradable Stents ranged from $395.67 Million to $704.63 Million. **Q: What applications are driving the demand for vascular stents?** A: The primary applications include Coronary Artery Disease, Peripheral Vascular Disease, and Carotid Artery Disease. **Q: What is the expected market size for Peripheral Vascular Disease stents by 2035?** A: The expected market size for Peripheral Vascular Disease stents is projected to reach $800.0 Million by 2035. **Q: Which end-use segments are most significant in the US vascular stents market?** A: Significant end-use segments include Hospitals, Cardiac Catheterization Labs, and Ambulatory Surgical Centers. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-vascular-stents-market-20083*